Procedure for relapsed/refractory disease must be determined depending on prior therapy and in addition The explanation why the initial cure was now not ideal (e.g., refractoriness vs. intolerance). Ibrutinib is the current gold typical therapy for patients with relapsed/refractory disorder, depending on the results of several section I-III trials,